Tumor Testing Reveals Hidden Inherited Cancer Risks
Genetic analysis of tumors identifies hereditary cancer-predisposition variants that standard diagnostic pathways may miss.
Updated on Nov. 6, 2026 in Cancer
Live Poll
Should doctors routinely test cancer patients' tumors for inherited risks to their families?
A study of tumors from 2,674 patients with solid cancers found that about 10 percent carried inherited genetic alterations linked to increased cancer risk. Researchers say standard diagnostic pathways could have missed roughly one-third of patients with hereditary cancer-predisposition syndrome.
Why it matters
Hereditary cancer risk can affect family members as well as the patient, so identifying inherited variants early may change screening and testing decisions. The findings suggest that routine tumor analysis could expand the detection of genetic risk beyond current clinical pathways.
The figures come from next-generation sequencing of more than 500 genes in roughly 2,700 tumor samples analyzed between January 2022 and December 2023. Sixteen percent of the identified variants fell in genes not normally tied to the patient's cancer, and it remains unclear how many carriers would be confirmed through follow-up testing of relatives.
The players
Fondazione Policlinico Universitario A. Gemelli IRCCS
A major hospital and research institute in Rome, Italy, known for oncology research and clinical care.
Genome Medicine
A peer-reviewed scientific journal that publishes research on genomics and its application to human disease.
The details
Researchers at the FPG500 program at Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome examined tumor samples for alterations suspected to be constitutional, or germline, alongside acquired tumor variants. Germline testing confirmed cancer-predisposing variants in about 10 percent of patients reviewed, and the findings were published in Genome Medicine.
Timeline
January 2022 to December 2023: Roughly 2,700 samples were analyzed during the program's first two years.
2022: The FPG500 program was launched at Fondazione Policlinico Gemelli.
Program Context
The study is an output of the FPG500 program, launched in 2022 at Fondazione Policlinico Gemelli in Rome, which applies next-generation sequencing across more than 500 genes. Its findings extend that program's tumor-sequencing work into the identification of inherited risk that standard clinical pathways do not always capture.
Patients whose tumor testing reveals a germline change may be advised to have relatives tested for the same variant. Those results could guide earlier screening or preventive decisions for family members.
The takeaway
Standard tumor diagnostics may not capture every inherited cancer risk, so patients with solid tumors may benefit from asking whether germline testing is appropriate. Because hereditary variants can affect relatives, the results can extend beyond the individual patient.
Further reading
For more on how inherited variants are identified in cancer care, see the Cancer section.
More information
Read the full Genome Medicine study on germline variant identification for the complete methods and results.
Source note: This article includes information reported by Newsweek.
Live Poll
Should doctors routinely test cancer patients' tumors for inherited risks to their families?
